GOVX insider transaction filings
GeoVax Labs, Inc. — 28 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-22. Screen GOVX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-22 | 4 | Morgan Jayne — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Lemerond Nicole — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | McKee Kelly T. Jr. — Chief Medical Officer | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Sharkey John W. — VP, Business Development | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Kollintzas Dean G — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Reynolds Mark — CFO | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | SPENCER JOHN N JR — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | NEWMAN MARK J — Chief Scientific Officer | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | DODD DAVID A — President, CEO, Director | Grant/award (A): 29,300 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | CHASE RANDAL D — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | MCNALLY ROBERT T — Director | Grant/award (A): 6,000 (derivative) @ $0 | EDGAR |
| 2025-10-20 | 4 | SPENCER JOHN N JR — Director | Purchase (P): 10,000 @ $0.55 | EDGAR |
| 2025-08-08 | 4 | McKee Kelly T. Jr. — Chief Medical Officer | Purchase (P): 1,107 @ $0.67 | EDGAR |
| 2025-06-06 | 4 | Morgan Jayne — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Lemerond Nicole — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | McKee Kelly T. Jr. — Chief Medical Officer | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Sharkey John W. — VP, Business Development | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Kollintzas Dean G — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Reynolds Mark — CFO | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | SPENCER JOHN N JR — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | NEWMAN MARK J — Chief Scientific Officer | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | DODD DAVID A — President, CEO, Director | Grant/award (A): 185,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | CHASE RANDAL D — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | MCNALLY ROBERT T — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | SPENCER JOHN N JR — Director | Purchase (P): 10,000 @ $0.98 | EDGAR |
| 2025-04-10 | 4 | Sharkey John W. — VP, Business Development | Purchase (P): 6,000 @ $0.99 | EDGAR |
| 2025-04-01 | 4 | DODD DAVID A — President, CEO, Director | Purchase (P): 10,000 @ $1.08 | EDGAR |
| 2025-03-31 | 4 | Reynolds Mark — CFO | Purchase (P): 6,800 @ $1.08 | EDGAR |
Recent 8-K events — GeoVax Labs, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-07-27 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-10 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-06-17 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GOVX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →